Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. ...

Isomorphic Labs, which was spun out of Google DeepMind, has also begun using the system internally to speed its efforts to discover new drugs.

Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as ...